No Data
Zhejiang Jolly Pharmaceutical (300181.SZ): Bailin capsules have officially been launched for sale.
On December 24, Gelonghui reported that Zhejiang Jolly Pharmaceutical (300181.SZ) announced on the investor interaction platform that the company’s Bailin capsules have officially launched for sale.
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Seems To Use Debt Quite Sensibly
Jolly Pharmaceutical to Take Controlling Stake in Lingyi Biotech in Cooperation Deal; Shares Up 3%
Zhejiang Jolly Pharmaceutical (300181.SZ): Signed a global strategy cooperation framework agreement with Lingyi Biotechnology.
On November 20th, Jolly Pharmaceutical (300181.SZ) announced that the company has signed a "Strategic Cooperation Framework Agreement" with Lingyi (Hangzhou) Biotechnology Co., Ltd. According to the agreement, the two parties will establish a long-term and in-depth strategic cooperation relationship. The main areas of cooperation include equity cooperation, research and development cooperation, sales cooperation, and product cooperation. In terms of equity cooperation, Jolly Pharmaceutical will increase its capital to become the second largest shareholder of Lingyi Biotech (Series A round). In terms of research and development cooperation, the two parties will jointly develop innovative drugs for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.
Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Jumps 6.5% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
